Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic859 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,531 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (621)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00795002 | Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2018 | clinicaltrials |
| NCT01452646 | Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia(AML1310) | completed | Phase 2 | 515 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Aug 6, 2018 |
| clinicaltrials |
| NCT01535391 | Nilotinib in PH+, BCR-, ABL+ CML Patients(CML0811) | completed | Phase 3 | 109 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Aug 6, 2018 | clinicaltrials |
| NCT01237808 | Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation | completed | Phase 3 | 144 | University of UlmOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00898079 | Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer | completed | — | 2,545 | Children's Oncology GroupNETWORK | 6 | Jul 19, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00467961 | Stem Cell Transplantation for Patients With Cancers of the Blood | completed | Phase 2 | 61 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 13, 2018 | clinicaltrials |
| NCT01872819 | Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay | completed | N/A | 16 | University of WashingtonOTHER | 1 | Jul 11, 2018 | clinicaltrials |
| NCT01517035 | Improving Blood Stem Cell Collection and Transplant Procedures | completed | Phase 1 / Phase 2 | 43 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02226861 | Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation | completed | Phase 1 | 24 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01768897 | CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 67 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT01053494 | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | completed | N/A | 80 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01352650 | Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML) | completed | Phase 1 | 71 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02662920 | Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML) | completed | — | 209 | Wake Forest University Health SciencesOTHER | 0 | Jul 2, 2018 | clinicaltrials |
| NCT02101983 | Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) | completed | N/A | 11 | University of RochesterOTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT00890929 | Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 45 | Stanford UniversityOTHER | 1 | Jun 18, 2018 | clinicaltrials |
| NCT00611247 | Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia | completed | Phase 2 | 42 | Bruno C. MedeirosOTHER | 1 | Jun 15, 2018 | clinicaltrials |
| NCT00070135 | Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission | completed | Phase 2 | 121 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 12, 2018 | clinicaltrials |
| NCT02895542 | Preparatory Work to Assess Adherence to Oral Chemotherapy | completed | — | 86 | Wake Forest University Health SciencesOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT01994837 | A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 32 | AbbVieINDUSTRY | 0 | Jun 6, 2018 | clinicaltrials |
| NCT02210858 | Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders | completed | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2018 | clinicaltrials |
| NCT02203825 | Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | completed | Phase 1 | 12 | Celyad Oncology SAINDUSTRY | 1 | Jun 1, 2018 | clinicaltrials |
| NCT00656448 | A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS | completed | Phase 3 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT01804101 | Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | N/A | 48 | Fred Hutchinson Cancer CenterOTHER | 1 | May 25, 2018 | clinicaltrials |
| NCT00666588 | Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 3 | May 22, 2018 | clinicaltrials |
| NCT00660920 | Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies | completed | Phase 1 | 81 | Ariad PharmaceuticalsINDUSTRY | 1 | May 16, 2018 | clinicaltrials |
| NCT00830518 | A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome | completed | Phase 2 | 57 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | May 11, 2018 | clinicaltrials |
| NCT02326584 | A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML | completed | Phase 1 | 116 | Seagen Inc.INDUSTRY | 1 | May 9, 2018 | clinicaltrials |
| NCT01200355 | Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome | completed | Phase 4 | 113 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 7, 2018 | clinicaltrials |
| NCT00539695 | Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD(IL2 for GVHD) | completed | Phase 2 | 25 | Baylor College of MedicineOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT01999413 | Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients(FAMYLY) | completed | Phase 2 | 30 | French Innovative Leukemia OrganisationOTHER | 1 | Apr 27, 2018 | clinicaltrials |
| NCT01460693 | Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia(SPIRIT2) | completed | Phase 3 | 814 | Newcastle UniversityOTHER | 1 | Apr 24, 2018 | clinicaltrials |
| NCT01819792 | Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia(LAMVIRE) | completed | Phase 4 | 119 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT00357032 | PXD101 in Treating Patients With Acute Myeloid Leukemia | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 17, 2018 | clinicaltrials |
| NCT02121418 | Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm | completed | N/A | 12 | University of WashingtonOTHER | 1 | Apr 13, 2018 | clinicaltrials |
| NCT01757639 | Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2018 | clinicaltrials |
| NCT01798901 | AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 13 | Alison WalkerOTHER | 1 | Mar 14, 2018 | clinicaltrials |
| NCT02283190 | 1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML) | completed | Phase 1 | 5 | Ashkan EmadiOTHER | 1 | Mar 12, 2018 | clinicaltrials |
| NCT00602225 | Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT01842139 | Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission | completed | Phase 1 | 7 | University of ChicagoOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT01779882 | Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT | completed | N/A | 72 | University Hospital, Basel, SwitzerlandOTHER | 1 | Mar 2, 2018 | clinicaltrials |
| NCT02204644 | The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML | completed | Phase 3 | 400 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT02395822 | MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients | completed | Phase 2 | 17 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT01491958 | Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation | completed | Phase 2 | 40 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT00875693 | A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML) | completed | Phase 1 | 47 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT02294552 | Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT | completed | Phase 2 | 200 | Ivan S MoiseevOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT00788892 | Trial of CPX-351 in Newly Diagnosed Elderly AML Patients | completed | Phase 2 | 126 | Jazz PharmaceuticalsINDUSTRY | 2 | Jan 12, 2018 | clinicaltrials |
| NCT00908167 | Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies | completed | Phase 1 | 44 | St. Jude Children's Research HospitalOTHER | 1 | Jan 12, 2018 | clinicaltrials |
| NCT00854646 | Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 22 | Traws Pharma, Inc.INDUSTRY | 1 | Jan 10, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Aug 7, 2018source: clinicaltrials